The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 inhibitors?

EUROPEAN JOURNAL OF HEART FAILURE

N/A

10.1002/ejhf.3245

WOS:001202978600001

https://hdl.handle.net/11368/3073341

info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85190945792

https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3245

open access

license:copyright editore

license:digital rights management non definito

license uri:iris.pri02

license uri:iris.pri00

https://arts.units.it/request-item?handle=11368/3073341